Answers are grounded in this paper and cite their sources.
Phase 1b trial shows ilofotase alfa enhances alkaline phosphatase in adults with hypophosphatasia, indicating effective enzyme replacement therapy.
Hypophosphatasia is a rare genetic disease caused by deficient alkaline phosphatase activity. In adults, this causes functional limitations, substantial disability with pain and reduced quality of life. This Phase 1b, single-center, open-label trial investigated ilofotase alfa, a fully human recombinant protein intended as enzyme replacement therapy, in adults with hypophosphatasia. Changes in plasma levels of alkaline phosphatase substrates inorganic pyrophosphate and pyridoxal 5’-phosphate were evaluated. Participants were randomized 1:1 to receive at 0.8 or 3.2 mg/kg ilofotase alfa intravenously over one hour. Twelve participants were enrolled and completed the trial. At baseline, all participants had reduced alkaline phosphatase activity and elevated pyridoxal 5’-phosphate. The greatest reduction in inorganic pyrophosphate and pyridoxal 5’-phosphate occurred two hours after start of dosing in both treatment groups. Across the 10-day follow-up period, inorganic pyrophosphate values returned to baseline levels more rapidly in the 0.8 mg/kg group compared with the 3.2 mg/kg group. Mean circulating alkaline phosphatase activity peaked 24 hours after dosing and subsequently declined but remained above the lower limit of normal throughout the study. A dose-proportional increase in ilofotase alfa was observed, reaching peak concentration one-hour post-infusion. Eight treatment-emergent adverse events occurred, all classified as mild. These data demonstrate that single-dose ilofotase alfa enhances alkaline phosphatase activity and results in dose-dependent reductions in primary disease-specific biomarkers without undesired effects on mineral homeostasis.
No takes yet. Share an insight, caveat, or question.
Seefried et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: